198 related articles for article (PubMed ID: 14749538)
1. Differential inhibition of endothelial cell proliferation and migration by urokinase subdomains: amino-terminal fragment and kringle domain.
Kim KS; Hong YK; Lee Y; Shin JY; Chang SI; Chung SI; Joe Y
Exp Mol Med; 2003 Dec; 35(6):578-85. PubMed ID: 14749538
[TBL] [Abstract][Full Text] [Related]
2. Integrin alphavbeta3 is not significantly implicated in the anti-migratory effect of anti-angiogenic urokinase kringle domain.
O E; Kim HK; Hong SH; Kim CK; Hong YK; Joe YA
Oncol Rep; 2008 Sep; 20(3):631-6. PubMed ID: 18695916
[TBL] [Abstract][Full Text] [Related]
3. Direct interaction of the kringle domain of urokinase-type plasminogen activator (uPA) and integrin alpha v beta 3 induces signal transduction and enhances plasminogen activation.
Tarui T; Akakura N; Majumdar M; Andronicos N; Takagi J; Mazar AP; Bdeir K; Kuo A; Yarovoi SV; Cines DB; Takada Y
Thromb Haemost; 2006 Mar; 95(3):524-34. PubMed ID: 16525582
[TBL] [Abstract][Full Text] [Related]
4. Anti-angiogenic activity of the recombinant kringle domain of urokinase and its specific entry into endothelial cells.
Kim KS; Hong YK; Joe YA; Lee Y; Shin JY; Park HE; Lee IH; Lee SY; Kang DK; Chang SI; Chung SI
J Biol Chem; 2003 Mar; 278(13):11449-56. PubMed ID: 12529357
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of anti-tumor activity by low-dose combination of the recombinant urokinase kringle domain and celecoxib in a glioma model.
Kim CK; Joe YA; Lee SK; Kim EK; O E; Kim HK; Oh BJ; Hong SH; Hong YK
Cancer Lett; 2010 Feb; 288(2):251-60. PubMed ID: 19664879
[TBL] [Abstract][Full Text] [Related]
6. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
[TBL] [Abstract][Full Text] [Related]
7. Amino-terminal fragment of urokinase inhibits tumor cell invasion in vitro and in vivo: respective contribution of the urokinase plasminogen activator receptor-dependent or -independent pathway.
Li H; Soria C; Griscelli F; Opolon P; Soria J; Yeh P; Legrand C; Vannier JP; Belin D; Perricaudet M; Lu H
Hum Gene Ther; 2005 Oct; 16(10):1157-67. PubMed ID: 16218777
[TBL] [Abstract][Full Text] [Related]
8. A hybrid protein comprising ATF domain of pro-UK and VAS, an angiogenesis inhibitor, is a potent candidate for targeted cancer therapy.
Sun Q; Xu Q; Dong X; Cao L; Huang X; Hu Q; Hua ZC
Int J Cancer; 2008 Aug; 123(4):942-50. PubMed ID: 18528863
[TBL] [Abstract][Full Text] [Related]
9. cDNA transfection of amino-terminal fragment of urokinase efficiently inhibits cancer cell invasion and metastasis.
Zhu F; Jia S; Xing G; Gao L; Zhang L; He F
DNA Cell Biol; 2001 May; 20(5):297-305. PubMed ID: 11410166
[TBL] [Abstract][Full Text] [Related]
10. The recombinant kringle domain of urokinase plasminogen activator inhibits VEGF165-induced angiogenesis of HUVECs by suppressing VEGFR2 dimerization and subsequent signal transduction.
Kim BM; Lee DH; Choi HJ; Lee KH; Kang SJ; Joe YA; Hong YK; Hong SH
IUBMB Life; 2012 Mar; 64(3):259-65. PubMed ID: 22252975
[TBL] [Abstract][Full Text] [Related]
11. Urokinase-type plasminogen activator mediates basic fibroblast growth factor-induced bovine endothelial cell migration independent of its proteolytic activity.
Odekon LE; Sato Y; Rifkin DB
J Cell Physiol; 1992 Feb; 150(2):258-63. PubMed ID: 1734031
[TBL] [Abstract][Full Text] [Related]
12. The recombinant kringle domain of urokinase plasminogen activator inhibits in vivo malignant glioma growth.
Kim CK; Hong SH; Joe YA; Shim BS; Lee SK; Hong YK
Cancer Sci; 2007 Feb; 98(2):253-8. PubMed ID: 17233842
[TBL] [Abstract][Full Text] [Related]
13. Mutation of human plasminogen kringle 1-5 enhances anti-angiogenic action via increased interaction with integrin alpha(v)beta(3).
Chang PC; Chang YJ; Wu HL; Chang CW; Lin CI; Wang WC; Shi GY
Thromb Haemost; 2008 Apr; 99(4):729-38. PubMed ID: 18392331
[TBL] [Abstract][Full Text] [Related]
14. Epitope mapping of the anti-urokinase monoclonal antibody 5B4 by isolated domains of urokinase.
Corti A; Sarubbi E; Soffientini A; Nolli ML; Zanni A; Galimberti M; Parenti F; Cassani G
Thromb Haemost; 1989 Nov; 62(3):934-9. PubMed ID: 2480654
[TBL] [Abstract][Full Text] [Related]
15. Domain-dependent action of urokinase on smooth muscle cell responses.
Tanski WJ; Fegley AJ; Roztocil E; Davies MG
J Vasc Surg; 2004 Jan; 39(1):214-22. PubMed ID: 14718842
[TBL] [Abstract][Full Text] [Related]
16. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect.
Resnati M; Guttinger M; Valcamonica S; Sidenius N; Blasi F; Fazioli F
EMBO J; 1996 Apr; 15(7):1572-82. PubMed ID: 8612581
[TBL] [Abstract][Full Text] [Related]
17. Amino-terminal fragment of urokinase-type plasminogen activator inhibits its plasminogen activation.
Sun Z; Zhang PX; Wang P; Gurewich V; Shen HY; Liu JN
Thromb Res; 2002 Apr; 106(2):105-11. PubMed ID: 12182908
[TBL] [Abstract][Full Text] [Related]
18. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice.
Min HY; Doyle LV; Vitt CR; Zandonella CL; Stratton-Thomas JR; Shuman MA; Rosenberg S
Cancer Res; 1996 May; 56(10):2428-33. PubMed ID: 8625323
[TBL] [Abstract][Full Text] [Related]
19. Modulation of invasive properties of human glioblastoma cells stably expressing amino-terminal fragment of urokinase-type plasminogen activator.
Mohanam S; Chandrasekar N; Yanamandra N; Khawar S; Mirza F; Dinh DH; Olivero WC; Rao JS
Oncogene; 2002 Nov; 21(51):7824-30. PubMed ID: 12420219
[TBL] [Abstract][Full Text] [Related]
20. Systematic mutational analysis of the receptor-binding region of the human urokinase-type plasminogen activator.
Magdolen V; Rettenberger P; Koppitz M; Goretzki L; Kessler H; Weidle UH; König B; Graeff H; Schmitt M; Wilhelm O
Eur J Biochem; 1996 May; 237(3):743-51. PubMed ID: 8647121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
